Encorafenib i binimetinib per al tractament de pacients adults amb melanoma no resecable o metàstasic amb mutucació BRAF V600
Abstract
Melanoma accounts for 4% of all malignant skin tumors, though it is responsible for 80% of deaths from this type of tumor. It is the most severe form of skin cancer and affects adults of all ages.
In Catalonia, 10.7 and 2.4 men out of every 100,000 are diagnosed and died every 100,000 respectively and 11.0 and 1.6 women respectively. Since 1994, its incidence has increased by 1.8% annually in men and has remained stable in women. Mortality remains stable in both men and women. 878 new cases of melanoma were detected and mortality was 175 cases in 2017.
Keywords
Encorafenib; Binimetinib; Advanced melanoma; BRAF V600
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Encorafenib i binimetinib per al tractament de pacients adults amb melanoma no resecable o metàstasic amb mutucació BRAF V600. Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4701This item appears in following collections
The following license files are associated with this item: